|
|
|
|
|
Click Here to return To Results
|
|
|
|
There was a significant improvement of the pramipexole group in UPDRS total scores, subscores part II, III (activities of daily living and motor examination), and IV (complications of therapy). Mean UPDRS totally score decreased by 37.3% un der pramipexole compared with 12.2% under placebo (p<0.001). Patients under pramipexole reported an overall reduction in "off" periods of 12%--resulting in 1.7 more hours "on" time a day-compared with an increase in "off" periods of 2% under placebo. Th ere were no unexpected safety results. The adverse event profile disclosed a high tolerability. The most important adverse events under pramipexole were fatigue, dyskinesia, and vivid dreams. Pramipexole administration is an efficacious and well tolera ted add on therapy in patients with advanced Parkinson's disease with an improvement in activities of daily living, motor function, and treatment associated complications. |
|
(click to filter results - removes previous filter)
activities of daily living
adverse drug reaction
disability rating scale,neurological
disability,neurological
dopamine agonist
dyskinesia
fatigue
Parkinson disease
Parkinson disease,fluctuations in
Parkinson disease,on-off phenomena in
Parkinson disease,treatment of
pramipexole
review article
treatment of neurologic disorder
Unified Parkinson Rating Scale
|
Click Here to return To Results
|
|